Rationale, design and objectives of two phase III, randomised, placebo-controlled studies of GLPG1690, a novel autotaxin inhibitor, in idiopathic pulmonary fibrosis (ISABELA 1 and 2)

Rationale, design and objectives of two phase III, randomised, placebo-controlled studies of GLPG1690, a novel autotaxin inhibitor, in idiopathic pulmonary fibrosis (ISABELA 1 and 2)

Introduction While current standard of care (SOC) for idiopathic pulmonary fibrosis (IPF) slows disease progression, prognosis remains poor. Therefore, an unmet need exists for novel, well-tolerated agents that reduce lung function decline and improve quality of life. Here we report the design of tw...

Full description

Bibliographic Details
Main Authors: Kevin K Brown, Toby M Maher, Michael Kreuter, David J Lederer, Wim Wuyts, Nadia Verbruggen, Simone Stutvoet, Ann Fieuw, Paul Ford, Walid Abi-Saab, Marlies Wijsenbeek
Format: Article
Language:English
Published: BMJ Publishing Group 2019-10-01
Series:BMJ Open Respiratory Research
Online Access:https://bmjopenrespres.bmj.com/content/6/1/e000422.full

Internet

https://bmjopenrespres.bmj.com/content/6/1/e000422.full

Similar Items